Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).
PSA screening reduces PCa-mortality but the disadvantages overdiagnosis and overtreatment require multivariable risk-prediction tools to select appropriate treatment or active surveillance. This review explains the differences between the two largest screening trials and discusses the drawbacks of screening and its meta-analysisxs. The current American and European screening strategies are described. Nonetheless, PSA is one of the most widely used tumor markers and strongly correlates with the risk of harboring PCa. However, while PSA has limitations for PCa detection with its low specificity there are several potential biomarkers presented in this review with utility for PCa currently being studied. There is an urgent need for new biomarkers especially to detect clinically significant and aggressive PCa. From all PSA-based markers, the FDA-approved prostate health index (phi) shows improved specificity over percent free and total PSA. Another kallikrein panel, 4K, which includes KLK2 has recently shown promise in clinical research studies but has not yet undergone formal validation studies. In urine, prostate cancer gene 3 (PCA3) has also been validated and approved by the FDA for its utility to detect PCa. The potential correlation of PCA3 with cancer aggressiveness requires more clinical studies. The detection of the fusion of androgen-regulated genes with genes of the regulatory transcription factors in tissue of (~)50% of all PCa-patients is a milestone in PCa research. A combination of the urinary assays for TMPRSS2:ERG gene fusion and PCA3 shows an improved accuracy for PCa detection. Overall, the field of PCa biomarker discovery is very exciting and prospective.
Department of Urology, Charité - UniversitätsmedizinBerlin, Germany; Berlin Institute for Urologic Research, Berlin, Germany.
Carsten
C
Stephan
IR2Dx , Los Osos, CA, USA.
Harry
H
Rittenhouse
Department of Urology, Charité - Universitätsmedizin Berlin, Germany.
Xinhai
X
Hu
Institute of Medical Informatics, Charité - Universitätsmedizin Berlin, Germany.
Henning
H
Cammann
Department of Urology, Charité - UniversitätsmedizinBerlin, Germany; Berlin Institute for Urologic Research, Berlin, Germany.
Klaus
K
Jung
Biomarkers; MPRSS2; PCA3; PSA; Prostate cancer; Prostate health index; Screening
Eur Urol. 2007 Jul;52(1):89-97
17257742
BMC Med. 2008 Jul 08;6:19
18611265
Nature. 2009 Feb 12;457(7231):910-4
19212411
Clin Chem. 1998 Dec;44(12):2471-9
9836714
Eur Urol. 2013 Jun;63(6):986-94
23375961
J Urol. 1999 Aug;162(2):293-306
10411025
Eur Urol. 2013 Oct;64(4):530-9
23759326
BMJ. 2010 Sep 14;341:c4543
20843937
J Urol. 1994 May;151(5):1283-90
7512659
Urology. 2012 Sep;80(3):656-60
22770616
Clin Chem. 2006 Jun;52(6):1089-95
16627561
BJU Int. 2008 Sep;102(7):799-805
18522632
Eur Urol. 2012 Apr;61(4):664-75
22169079
Eur Urol. 2013 Jan;63(1):101-7
22980443
Eur J Cancer. 2013 Apr;49(6):1374-403
23485231
Carcinogenesis. 2013 Oct;34(10):2281-5
23698636
Eur Urol. 2012 Dec;62(6):976-83
22698574
N Engl J Med. 2004 May 27;350(22):2239-46
15163773
N Engl J Med. 2012 Mar 15;366(11):981-90
22417251
JAMA. 1998 May 20;279(19):1542-7
9605898
Evid Based Med. 2011 Feb;16(1):20-1
21228057
Ann Clin Biochem. 2010 May;47(Pt 3):282
20233752
Cancer Res. 1991 Jan 1;51(1):222-6
1703033
Eur Urol. 2012 Nov;62(5):745-52
22704366
Oncotarget. 2013 Apr;4(4):542-9
23625538
Curr Opin Urol. 2013 May;23(3):239-44
23548978
Nat Rev Urol. 2013 Jan;10(1):38-48
23247693
J Urol. 2008 Apr;179(4):1587-92
18295257
Eur Urol. 2009 Oct;56(4):584-91
19660851
Urology. 2009 Oct;74(4):873-7
19476981
Clin Chem. 2003 Feb;49(2):253-9
12560348
Clin Chim Acta. 2012 Aug 16;413(15-16):1274-8
22542564
Int J Cancer. 2014 Jan 1;134(1):197-206
23797698
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):373-7
15006911
Urology. 2002 Jun;59(6):797-802
12031356
Ann Intern Med. 2012 Jul 17;157(2):120-34
22801674
BJU Int. 2013 Oct;112(6):717-28
22759214
Semin Cancer Biol. 1999 Apr;9(2):83-93
10202130
BMJ. 2013 Apr 15;346:f2023
23596126
J Urol. 2013 Aug;190(2):419-26
23659877
Int J Mol Sci. 2013 Jul 04;14(7):13893-908
23880848
Nat Rev Cancer. 2008 Apr;8(4):268-78
18337732
J Urol. 2013 Dec;190(6):2271-7
23665271
Clin Chem. 2013 Jan;59(1):306-14
23213080
Clin Chem. 2004 Jun;50(6):1017-25
15054080
Tumour Biol. 2013 Jun;34(3):1337-47
23504524
Clin Chem. 2000 Oct;46(10):1610-8
11017939
Int J Urol. 2012 Feb;19(2):100-8
22103653
Prostate. 2012 Nov;72(15):1611-21
22430630
Urol Oncol. 2013 Jul;31(5):566-71
21600800
S Afr Med J. 2012 Jun 28;102(8):677-9
22831945
Eur Urol. 2009 Oct;56(4):659-67
19304372
Eur Urol. 2013 Feb;63(2):201-9
22854248
Urology. 2006 Apr;67(4):762-8
16600352
N Engl J Med. 2012 Jun 7;366(23):2229; author reply 2230-1
22670915
Eur Urol. 2014 Feb;65(2):329-36
23954085
Cancer Lett. 2007 Apr 28;249(1):18-29
17292541
BJU Int. 2003 Dec;92(9):932-5
14632850
Clin Chem. 2013 Jan;59(1):280-8
23213079
BJU Int. 2012 Oct;110 Suppl 1:3-7
23046034
J Clin Oncol. 2012 Jul 20;30(21):2581-4
22711853
Urology. 2000 Sep 1;56(3):418-22
10962306
Clin Trials. 2010 Aug;7(4):303-11
20571134
BJU Int. 2013 May;111(6):914-20
23320782
Eur Urol. 2012 Apr;61(4):851-4
22285762
Eur J Cancer. 2007 Sep;43(13):1918-26
17689069
CA Cancer J Clin. 2013 Jan;63(1):11-30
23335087
BJU Int. 2010 Aug;106(3):304-15
20653654
Lancet Oncol. 2010 Aug;11(8):725-32
20598634
Sci Transl Med. 2011 Aug 3;3(94):94ra72
21813756
Eur Urol. 2008 Nov;54(5):1081-8
18602209
Thromb Haemost. 2013 Sep;110(3):484-92
23903407
Clin Cancer Res. 2010 Jun 15;16(12):3232-9
20400522
Clin Chem. 1999 Jun;45(6 Pt 1):814-21
10351990
Ann Intern Med. 2012 Jul 17;157(2):137-8
22801676
J Urol. 2011 May;185(5):1650-5
21419439
Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1133-47
11097220
Eur Urol. 2010 Jul;58(1):12-8; discussion 20-1
20117878
Clin Chem Lab Med. 2013 Apr;51(4):729-39
23154423
Clin Chem. 1991 Sep;37(9):1618-25
1716536
Anticancer Res. 2009 Jul;29(7):2589-600
19596933
Endocr Rev. 2001 Apr;22(2):184-204
11294823
J Urol. 2013 Feb;189(2):422-9
23017522
Prostate. 2013 Jan;73(2):113-20
22674214
J Natl Cancer Inst. 2012 Jan 18;104(2):125-32
22228146
Eur Urol. 2010 Jul;58(1):46-52
20362385
Clin Chem. 2006 Jan;52(1):59-64
16391327
N Engl J Med. 2009 Mar 26;360(13):1320-8
19297566
Eur Urol. 2012 Jan;61(1):1-7
21862205
Ann Intern Med. 2011 Dec 6;155(11):762-71
21984740
Science. 2005 Oct 28;310(5748):644-8
16254181
Eur Urol. 2012 Apr;61(4):652-61
22134009
Eur Urol. 2013 Sep;64(3):347-54
23856038
Eur Urol. 2010 Jun;57(6):921-7
20189711
Eur Urol. 2014 Mar;65(3):534-42
23201468
Int J Biol Markers. 2009 Apr-Jun;24(2):65-9
19634108
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1193-200
20447916
Asian J Androl. 2013 May;15(3):333-9
23524531
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720
23440794
Clin Chem. 2005 Aug;51(8):1342-51
15961552
Mod Pathol. 2010 Apr;23 (4):539-46
20118910